Skip to content
Biodatica
Start free

Hutchmed

Changsha

OncologyantibodyPhase IIListed · HCM

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

2mo agoTrial registeredMay 13, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Momentum 82 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Dec 1, 2025

    ALL, Adult · WITHDRAWN · sponsor: Institute of Hematology & Blood Diseases Hospital, China · Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

    ClinicalTrials.gov · NCT06570915 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Sep 29, 2024

    AML (Acute Myelogenous Leukemia) · RECRUITING · sponsor: Institute of Hematology & Blood Diseases Hospital, China · Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

    ClinicalTrials.gov · NCT06635681 (opens the source filing in a new tab)

  3. Trial

    NA registered

    Aug 13, 2024

    AML · RECRUITING · sponsor: Institute of Hematology & Blood Diseases Hospital, China · Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

    ClinicalTrials.gov · NCT06529250 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    May 27, 2024

    Hematological Malignancies · RECRUITING · sponsor: Hutchmed · A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

    ClinicalTrials.gov · NCT06387082 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources